Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly Gets Approvable Letter for Arxxant | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Lilly Gets Approvable Letter for Arxxant

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eli Lilly and Co. received an approvable letter from the FDA for ruboxistaurin mesylate (proposed trade name Arxxant), its investigational oral therapy for treatment of diabetic retinopathy (DR), a diabetic eye disease.

As part of the letter, the FDA has requested additional data to support the clinical evidence presented by the company in its NDA. Lilly plans to meet with the FDA to determine whether this request can be satisfied with data from an ongoing study or whether a new study is required.

“We will be working closely with the FDA to address issues outlined in the approvable letter and to define the pathway forward,” said Dr. Timothy R. Franson, Lilly’s vice president of global regulatory affairs.

Arxxant works by limiting the overactivation of protein kinase C beta (PKC b), a naturally occurring enzyme that has been linked to the development of diabetic retinopathy. It is the first of a new class of compounds being investigated for the treatment of moderate to severe non-proliferative diabetic retinopathy.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics